3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
11
NIH
2
NETWORK
2
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Neoplasms
5
Uterine Cervical Neoplasms
3
Breast Neoplasms
3
Uterine Cervical Dysplasia
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Skin Neoplasms
1
Sarcoma, Endometrial Stromal
1
Precancerous Conditions
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Leiomyosarcoma
1
Leiomyoma
1
Head and Neck Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
72
Cisplatin
57
Cetuximab
38
Fluorouracil
25
Nivolumab
21
Radiotherapy
20
Carboplatin
19
Paclitaxel
14
Docetaxel
11
Cyclophosphamide
9
Gefitinib
8
fludarabine
7
durvalumab
7
zalutumumab
6
atezolizumab
6
Drug Therapy
6
Bleomycin
6
epacadostat
5
cemiplimab
5
Radiotherapy, Intensity-Modulated
5
Pemetrexed
5
Ipilimumab
5
Gemcitabine
5
Afatinib
5
spartalizumab
4
Standard of Care
4
Radiation
4
Injections
4
Immune Checkpoint Inhibitors
4
Fibroblast Growth Factor 7
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Head and Neck Neoplasms
×
Biopsy
×
Clear all
NCT07327489
2026-01-08
ELEPHAS-05
Elephas
Recruiting
2,000 enrolled